ABSTRACT
A series of novel pyridine-2-propanoic acids was synthesized. A structure-activity relationship study of these compounds led to the identification of potent dual PPARalpha/gamma agonists with varied isoform selectivity. Based on the results of efficacy studies in diabetic (db/db) mice, and the desired pharmacokinetic parameters, compound (S)-13 was selected for further profiling.
Subject(s)
Hypoglycemic Agents/chemical synthesis , Hypoglycemic Agents/pharmacology , PPAR alpha/agonists , PPAR gamma/agonists , Pyridines/chemistry , Pyridines/pharmacology , Animals , Blood Glucose/metabolism , Body Weight/drug effects , Cell Line, Tumor , Diabetes Mellitus/blood , Diabetes Mellitus/drug therapy , Diabetes Mellitus/pathology , Humans , Hypoglycemic Agents/chemistry , Hypoglycemic Agents/therapeutic use , Male , Mice , Molecular Structure , PPAR alpha/metabolism , PPAR gamma/metabolism , Pyridines/chemical synthesis , Pyridines/therapeutic use , Structure-Activity RelationshipABSTRACT
A series of novel pyridine-3-propanoic acids was synthesized. A structure-activity relationship study of these compounds led to the identification of potent dual PPARalpha/gamma agonists with varied isoform selectivity. Based on the results of efficacy studies in diabetic (db/db) mice, and the desired pharmacokinetic parameters, compounds (S)-14 and (S)-19 were selected for further profiling.
